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Abstract
Background: Efforts to ease administration and enhance acceptability of the oral anti-malarial artemether-
lumefantrine (A-L) crushed tablet to infants and children triggered the development of a novel dispersible tablet of
A-L. During early development of this new formulation, two studies were performed in healthy subjects, one to
evaluate the palatability of three flavours of A-L, and a second one to compare the bioavailability of active
principles between the dispersible tablet and the tablet (administered crushed and intact).
Methods: Study 1 was performed in 48 healthy schoolchildren in Tanzania. Within 1 day, all subjects tasted a
strawberry-, orange- and cherry-flavoured oral A-L suspension for 10 seconds (without swallowing) in a
randomized, single-blind, crossover fashion. The palatability of each formulation was rated using a visual analogue
scale (VAS). Study 2 was an open, randomized crossover trial in 48 healthy adults given single doses of A-L (80 mg
artemether + 480 mg lumefantrine) with food. The objectives were to compare the bioavailability of artemether,
dihydroartemisinin (DHA) and lumefantrine between the dispersible tablet and the tablet administered crushed
(primary objective) and intact (secondary objective).
Results: Study 1 showed no statistically significant difference in VAS scores between the three flavours but cherry
had the highest score in several ratings (particularly for overall liking). Study 2 demonstrated that the dispersible
and crushed tablets delivered bioequivalent artemether, DHA and lumefantrine systemic exposure (area under the
curve [AUC]); mean ± SD AUC0-tlast were 208 ± 113 vs 195 ± 93 h.ng/ml for artemether, 206 ± 81 vs 199 ± 84 h.
ng/ml for DHA and 262 ± 107 vs 291 ± 106 h.μg/ml for lumefantrine. Bioequivalence was also shown for peak
plasma concentrations (Cmax) of DHA and lumefantrine. Compared with the intact tablet, the dispersible tablet
resulted in bioequivalent lumefantrine exposure, but AUC and Cmax values of artemether and DHA were 20-35%
lower.
Conclusions: Considering that cherry was the preferred flavour, and that the novel A-L dispersible tablet
demonstrated similar pharmacokinetic performances to the tablet administered crushed, a cherry-flavoured A-L
dispersible tablet formulation was selected for further development and testing in a large efficacy and safety study
in African children with malaria.
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In the treatment of uncomplicated malaria, there is an
urgent need for alternative formulations that offer
increased ease of administration, accuracy of dosing and
compliance for infants and children [1], the main target
population of artemisinin-based combination therapy
(ACT) in Africa. In fact, for children almost all forms of
ACT are available as crushed tablet only. The latter con-
trasts with the paediatric nature of the disease and the
bitterness of ingredients. This was the impetus behind
the development of a novel dispersible tablet formula-
tion of artemether-lumefantrine (A-L), the most widely
used ACT in Africa [2,3], ahead of the World Health
Organization’s call to make medicines child-friendly [4]
and the recent recommendation to deploy ACT formu-
lations appropriate for children [5].
In 2004, the A-L tablet (Coartem® ) became the first
fixed-dose ACT to be prequalified by the World Health
Organization, and received approval from the Food and
Drug Administration in the US in April 2009 [6]. This
tablet formulation, containing 20 mg of artemether and
1 2 0m go fl u m e f a n t r i n e ,h a sb e e np r o v e nt ob e
efficacious and safe in the treatment of uncomplicated
Plasmodium falciparum malaria when administered in a
six-dose regimen for 3 days [7,8]. In terms of drug dis-
position, artemether and lumefantrine exhibit comple-
mentary pharmacokinetic characteristics. After oral
administration, artemether is absorbed quickly, achiev-
ing maximum plasma concentrations (Cmax)a f t e r
approximately 2 hours. It is rapidly and extensively
demethylated to the pharmacologically active metabolite
dihydroartemisinin (DHA). Both artemether and DHA
exhibit short elimination half-lives of < 3 hours [9,10].
Lumefantrine is slowly absorbed reaching Cmax after
a p p r o x i m a t e l y6 - 8h o u r s ,a n di sm o r es l o w l yc l e a r e d
with an elimination half-life of 3-6 days [10-12], thereby
preventing recrudescence by destroying any residual
parasites that remain after artemether and DHA have
been cleared from the body [13]. Lumefantrine has
never been used as a monotherapy and has therefore
been protected from the development of parasite resis-
tance unlike partner drugs used in other forms of ACT.
Food intake significantly enhances the bioavailability of
both artemether and lumefantrine, an effect which is far
more pronounced for the lipophilic lumefantrine
[13-15]. There is good evidence that a standard African
diet is adequate to ensure optimal efficacy for A-L [16].
The pharmacokinetic features of artemether and lume-
fantrine are similar in children, when dosed according
to their body weight, compared with adults [13].
When treating paediatric malaria patients, A-L tablets
u s u a l l yh a v et ob ec r u s h e dp r i o rt oa d m i n i s t r a t i o nt o
infants and young children. The crushed tablets, similarly
to other anti-malarials, have a bitter taste that may cause
children to spit out or vomit the drug, potentially result-
ing in underdosing [3] or in overdosing if re-dosed.
A dispersible tablet containing the same amounts of arte-
mether and lumefantrine like the standard tablet would
allow a more accurate dosing of A-L and a simpler
administration to sick children and infants compared
with the tablet administered crushed [3]. As palatability
is a contributing factor to compliance, particularly in
children’s medicine [17], the success of dispersible A-L in
terms of acceptability to children would also be depen-
dent on a flavour that masks the bitter taste of the
drug [3].
Against this background, two studies were performed
during early clinical development of A-L dispersible
tablet. The first study evaluated the palatability of three
flavours of A-L in healthy African schoolchildren (Study
1), followed by a second study which assessed the rela-
tive bioavailability of artemether, DHA and lumefantrine
from A-L dispersible tablet compared with the tablet
administered crushed (primary objective) and intact
(secondary objective) in healthy European adults (Study
2). Study 1 was performed in schoolchildren rather than
infants because palatability assessments in infants were
considered not reliable. Furthermore, to standardize
study conditions as much as possible, palatability was
assessed at one centre in one country where malaria is
endemic. For study 2, healthy adults were selected to
avoid cumbersome blood collection in infants or chil-
dren. The latter appeared justified given the similarity of
artemether and lumefantrine pharmacokinetics between
adults and children [13].
For convenience of the reader, methods and results
a r ec o n s e c u t i v e l yp r e s e n t e df o rs t u d y1 ,f o l l o w e db yt h e
respective sections for study 2.
Methods
Study 1: Palatability study
Study design
The palatability study was conducted at a primary
school in Ifakara town, Tanzania, East Africa. Forty-
eight healthy male and female children, aged 7-10 years,
were enrolled, stratified by gender (24 girls and 24
boys). In the absence of previous tasting data on A-L,
the sample size was based on practical considerations.
The study protocol was reviewed and approved by the
Independent Ethics Committee of the Ifakara Health
Institute, Dar es Salaam, Tanzania, and written informed
consent was obtained from the parents or legal guar-
dians of the children before enrolment. For inclusion,
the subjects had to be able to hold 2 ml of apple juice
in their mouth for 10 seconds without swallowing and
to complete a questionnaire. Exclusion criteria included
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the sense of smell and taste, ingestion of any medication
(except paracetamol) or significant illness within the
previous two weeks, history of autonomic dysfunction,
bronchospastic disease or atopic allergy, known hyper-
sensitivity to any drug or artificial sweetener, and parti-
cipation in any clinical investigation within the previous
four weeks.
Three flavours of A-L were considered best in mask-
ing the bitter taste. The study was conducted similar
to those previously reported [18,19]. In brief, the sub-
jects received 2 ml of an oral suspension containing
20 mg of artemether and 120 mg of lumefantrine
(strawberry-, orange- or cherry-flavoured) in a rando-
mized, single-blind, crossover fashion. Study drug was
administered into the mouth cavity using a 10 ml
volume plastic syringe. The amount given represented
half a treatment dose for children of this age. Follow-
ing administration, the subject moved the study drug
within the mouth cavity and then held it in the mouth
for approximately 10 seconds. The study drug was not
swallowed. All formulations had a yellow appearance
to prevent any subject bias. The trial medication was
provided as powder-in-bottle formulations; the oral
suspension was prepared immediately prior to tasting.
No food or beverage was allowed for two hours before
the study commenced. The three administrations were
performed within one day, separated by 45-minute
intervals.
Determination of palatability
Immediately after each test dose, the child was asked to
separately rate the flavour, smell, sweetness and overall
liking of the medicine using a modified 100 mm visual
analogue scale (VAS) that incorporated a facial hedonic
scale [18,19]. The rating for overall liking was repeated
at 2-5 minutes after the study drug had been spat out.
In addition, 15-20 minutes after the last administration
had been rated the children were asked which of the
three administrations they thought tasted best (a rank-
ing from 1 to 3 was performed). Any adverse events
occurring during the study were recorded, with a final
assessment at one hour following last drug administra-
tion. The VAS scores were analysed to determine
whether a significant difference exists between flavours,
using a SAS PROC MIXED procedure (e.g. using linear
mixed effects modelling). The ranked data were analysed
by Friedman’s non-parametric procedure. All statistical
tests employed a level of significance of 0.05.
Results
Study 1: Palatability study
All 48 randomized children completed the study. The
mean age ± standard deviation (SD) was 8.6 ± 0.7 years.
All study participants were of black ethnicity.
All flavours were highly rated with mean VAS scores
ranging between 70 and 87 mm. As no significant gen-
der difference was observed, data from girls and boys
were pooled. There was no significant difference in
pooled VAS scores between the three flavours for any
rating. Numerically, cherry had the highest score in
overall liking (immediately after administration and
2-5 minutes thereafter) and in the rating for flavour
( F i g u r e1 ) .T h ea n a l y s i so fr a n k e dd a t ao nt h eo v e r a l l
preference of a flavour also indicated the absence of a
significant difference (P = 0.146).
Two mild adverse events (fever and clinical malaria)
unrelated to study medication were reported which
resolved upon treatment.
Methods
Study 2: Relative bioavailability study
Study design
This was an open-label, randomized, 3-period, 2-
sequence, crossover study conducted at Mediscis,
Lagord, France. A total of 48 healthy male and female
adults between 18 and 50 years of age were recruited.
The study protocol was approved by an Independent
Ethics Committee (The Consultative Committee for the
Protection of Persons in Biomedical Research, Poitiers
Cedex, France). Subjects gave written informed consent
to participate after being informed about the study. The
three study treatments consisted of a single oral dose of
A-L (4 dispersible tablets or 4 tablets of Coartem®, both
corresponding in total to 80 mg of artemether and
480 mg of lumefantrine, a standard dose in patients),
immediately (within 5 minutes) after consumption of a
meal (FDA breakfast [20]). A-L was administered as: (A)
4 dispersible tablets following dispersion in water; (B) 4
tablets crushed and dispersed in water; or (C) 4 intact
(uncrushed) tablets swallowed with water. Each subject
received all 3 treatments. Treatments A and B were
administered in study periods 1 and 2 in a randomized
crossover fashion; Treatment C was always administered
in study period 3. The treatments were separated by a
4-week washout.
Subjects and assessments
Subjects were judged healthy at screening (i.e. within
three weeks before first dosing) on the basis of medical
history, physical examination, vital signs measurements,
electrocardiogram, laboratory assessments, negative
urine drug and cotinine screens, and negative hepatitis
and human immunodeficiency virus serologies. For
inclusion, female subjects of childbearing age were
required to use reliable methods of contraception during
t h es t u d y .S u b j e c t sw e r ee x c l u d e di ft h e yh a dah i s t o r y
of autonomic dysfunction, bronchospastic disease, atopic
allergy, or hypersensitivity to the study drug or related
compounds. With the exception of contraceptives for
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no medication other than the study drug was allowed
during the study.
Subjects were confined to the study center from 12-
14 hours before until 48 hours after each drug adminis-
tration. The study medication was prepared by a site
pharmacist and administered immediately after a stan-
dard FDA breakfast by the study personnel as follows:
Treatment A, fully dispersed in non-carbonated water;
Treatment B, swallowed with non-carbonated water after
crushing in a mortar to coarse particles; Treatment C,
swallowed with non-carbonated water without previous
crushing. For Treatments A and B, study drug and 40 ml
of water were combined in a beaker followed by gentle
shaking. After ingestion, another 40 ml of water was
added to the beaker for rinsing; this additional volume
was also consumed by the subject. In total, 240 ml of
non-carbonated water were ingested for each treatment.
Safety assessments included physical examinations,
electrocardiograms, vital signs measurements (blood pres-
sure, pulse), and laboratory evaluations (biochemistry,
hematology, urinalysis) prior to the study, at multiple
times during the trial, and at study completion (last day
of the last treatment period). The assessments during the
study consisted of laboratory parameters (biochemistry,
haematology) 24, 48, 72, 96 and 120 hours post-dose;
vital signs at pre-dose as well as 24 and 48 hours there-
after, and an electrocardiogram pre-dose and 2, 8, 10, 12,
24, 36 and 48 hours post-dose. In addition, adverse event
monitoring took place.
Blood samples for artemether and DHA analysis (3.5 ml)
were collected before drug intake and at 0.5, 0.75, 1, 1.5, 2,
3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours after dosing. For
lumefantrine measurements, blood sampling (2.5 ml)
o c c u r r e da tp r e - d o s ea n da t0 . 5 ,1 ,1 . 5 ,2 ,3 ,4 ,5 ,6 ,8 ,1 0 ,
12, 16, 24, 36, 48, 72, 96, 120, 168, 216 and 264 hours
post-dose. All blood samples were taken by venepuncture
into heparin-coated tubes. After centrifugation, aliquots of
plasma were taken and frozen at -70°C until analysis.
Bioanalytics
Artemether and DHA were measured in plasma using a
reversed-phase high-performance liquid chromatography
(HPLC) with atmospheric pressure chemical ionization
(APCI) and mass spectrometry (MS) detection (with
modifications from [21]); the limit of quantification
(LOQ) was 5.0 ng/ml for both analytes. Lumefantrine
was measured in plasma by HPLC with tandem
mass spectrometry (MS/MS) detection; the LOQ was
50 ng/ml. The within-study assay validation showed an
assay precision (percent coefficient of variation [%CV])
of 3.8 to 6.3%, with a deviation (bias) of -4.7 to 5.0% of
nominal concentrations (0.1, 2.0 and 16.0 μg/ml).
Pharmacokinetic and statistical evaluation
Artemether, DHA and lumefantrine plasma concentra-
t i o n - t i m ep r o f i l e sw e r ea n a l y s e db ys t a n d a r dn o n - c o m -
partmental methods using WinNonlin Pro, Version
5.0.1, Pharsight Corporation, Mountain View, CA, USA.
The following pharmacokinetic parameters were deter-
mined: Cmax,t max (time of Cmax), area under the curve
calculated with the linear trapezoidal method from 0 h
to the time of the last quantifiable plasma concentration
(AUC0-tlast), AUC extrapolated to time infinity (AUC0-
inf) and terminal elimination half-life (t1/2). The slope of
the linear regression analysis from the last three (or
more) log concentration-time points was used to deter-
mine the terminal elimination rate constant (lz) and t1/
2 (t1/2 = ln2/lz).
Logarithmic-transformed Cmax,A U C 0-tlast and AUC0-
inf values were compared using linear mixed-effects
models with sequence, period and treatment as fixed
effects and subject nested in sequence as random effect.
T h et r e a t m e n td i f f e r e n c ee s t i m a t eo nt h el o g - s c a l ea n d
its 90% confidence interval (CI) were calculated; these
estimates were back-transformed, and the resulting ratio
Figure 1 Mean VAS palatability scores (24 girls, 24 boys). VAS = visual analogue scale. I did not like it = VAS score of 0 mm; I liked it very
much = VAS score of 100 mm. As no significant gender difference was observed, data from girls and boys were pooled. There was no
significant difference in pooled VAS scores between the three flavours for any rating (data not shown for smell and sweetness).
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intention of the study to prove bioequivalence between
treatments, the 90% CIs were compared with the stan-
dard bioequivalence range of 0.80-1.25 [22]. The com-
parison of artemether, DHA and lumefantrine exposure
after administration of the dispersible tablet (Treatment
A) versus the tablet administered crushed (Treatment B)
was the primary study objective, with lumefantrine AUC
prospectively defined as the key study endpoint. Com-
parisons between the dispersible tablet and intact tablet
(Treatment C) were secondary objectives.
Based on an intra-subject variability of 44% for lume-
fantrine AUC assessed in a previous study with Coar-
tem® (Novartis, data on file), a sample size of 48 subjects
was calculated. This ensured at least 80% power to
obtain a 90% CI for lumefantrine AUC within 0.77 and
1.30 [23].
Results
Study 2: Relative bioavailability study
All 48 randomized subjects (22 females, 26 males) com-
pleted the study. The mean age ± SD was 33.1 ± 7.8
years and mean weight was 68.3 ± 9.8 kg. Most study
participants (98%) were Caucasian, one subject was of
mixed ethnicity (Black-Caucasian).
Pharmacokinetic parameters of artemether, DHA and
lumefantrine and results of statistical analysis are
summarized in Tables 1 and 2, respectively. The corre-
sponding mean plasma concentration-time profiles are
shown in Figure 2.
All artemether and DHA pre-dose concentrations
were below the LOQ indicating the absence of any
carry-over effect between study periods. In a number of
subjects, log-linear regression analysis did not allow for
a proper assessment of the terminal elimination rate
constant (adjusted r
2 < 0.75). Hence, associated para-
meters (i.e. t1/2 and AUC0-inf)c o u l dn o ta l w a y sb e
determined. For lumefantrine, 5 pre-dose concentrations
were above the LOQ (range, 0.05 to 0.11 μg/ml) in
study period 2. In period 3, 12 pre-dose concentrations
were above the LOQ (range, 0.05 to 0.14 μg/ml). How-
ever, all of these pre-dose concentrations were ≤ 2.7%
of Cmax in the respective plasma concentration-time
profile, indicating the absence of a relevant carry-over
effect [22].
Dispersible tablet versus tablet administered crushed
Following administration of A-L as dispersible tablet
(Treatment A) and crushed tablet (Treatment B), arte-
mether, DHA and lumefantrine pharmacokinetics were
similar. Standard bioequivalence criteria (90% CIs for
the ratio of geometric means within 0.80 and 1.25) were
met for AUC0-tlast and AUC0-inf of artemether, DHA
and lumefantrine. Likewise, the 90% CIs for DHA and
Table 1 Relative bioavailability study - pharmacokinetic parameters of artemether, dihydroartemisinin and
lumefantrine in healthy subjects (n = 48)
Treatment A
dispersible tablet
Treatment B
crushed tablet
Treatment C
intact tablet
Artemether
tmax (hours) 2.0 (0.5-6.0) 2.0 (0.5-6.0) 2.0 (0.8-6.0)
Cmax (ng/ml) 58.4 ± 32.2 48.0 ± 22.2 83.8 ± 59.7
AUC0-tlast (h.ng/ml) 208 ± 113 195 ± 93 259 ± 150
AUC0-inf (h.ng/ml) 281 ± 120 (n = 24)* 261 ± 116 (n = 20)* 330 ± 158 (n = 33)*
t1/2 (hours) 2.2 ± 1.5 (n = 29, 60%)* 2.7 ± 2.2 (n = 25, 52%)* 2.3 ± 1.9 (n = 36, 75%)*
Dihydroartemisinin
tmax (hours) 2.0 (0.8-6.0) 2.5 (1.0-8.0) 2.0 (0.8-6.0)
Cmax (ng/ml) 57.3 ± 24.9 50.0 ± 18.9 90.4 ± 48.9
AUC0-tlast (h.ng/ml) 206 ± 81 199 ± 84 285 ± 98
AUC0-inf (h.ng/ml) 266 ± 80 (n = 26)* 261 ± 84 (n = 25)* 326 ± 103 (n = 38)*
t1/2 (hours) 2.1 ± 0.9 (n = 28, 58%)* 2.2 ± 1.1 (n = 27, 56%)* 2.3 ± 1.5 (n = 39, 81%)*
Lumefantrine
tmax (hours) 8.0 (6.0-12.0) 8.0 (6.0-12.0) 8.0 (5.0-12.0)
Cmax (μg/ml) 9.9 ± 3.0 10.8 ± 2.8 9.8 ± 4.2
AUC0-tlast (h.μg/ml) 262 ± 107 291 ± 106 243 ± 117
AUC0-inf (h.μg/ml) 279 ± 106 (n = 46)* 316 ± 119 (n = 47)* 281 ± 133 (n = 40)*
t1/2 (hours) 118 ± 55 (n = 46, 96%)* 115 ± 32 (n = 47, 98%)* 119 ± 51 (n = 41, 85%)*
*Reduced sample size because log-linear regression analysis did not allow for a proper assessment of the terminal elimination rate constant (adjusted r
2 < 0.75)
or extrapolated area contributed > 20% of the total AUC0-inf.
Data are median (range) for tmax and mean ± SD for all other parameters. A single oral dose of 80 mg of artemether and 480 mg of lumefantrine was
administered.
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Parameter Ratio (90% CI)*
Treatment A (dispersible tablet) vs B (crushed tablet) (primary analysis)
Artemether AUC0-inf AUC0-tlast Cmax 0.94 (0.86-1.02) 1.03 (0.94-1.13) 1.17 (1.06-1.29)
Dihydroartemisinin AUC0-inf AUC0-tlast Cmax 1.05 (0.99-1.11) 1.03 (0.93-1.15) 1.14 (1.04-1.24)
Lumefantrine AUC0-inf AUC0-tlast Cmax 0.90 (0.85-0.95) 0.89 (0.84-0.94) 0.91 (0.86-0.96)
Treatment A (dispersible tablet) vs C (intact tablet) (secondary analysis)
Artemether AUC0-inf AUC0-tlast Cmax 0.80 (0.71-0.90) 0.80 (0.73-0.88) 0.73 (0.65-0.82)
Dihydroartemisinin AUC0-inf AUC0-tlast Cmax 0.78 (0.72-0.84) 0.69 (0.62-0.77) 0.65 (0.58-0.73)
Lumefantrine AUC0-inf AUC0-tlast Cmax 1.06 (0.96-1.16) 1.12 (1.02-1.23) 1.07 (0.97-1.18)
*Ratio (90% CI) = ratio of the geometric means and 90% confidence interval for the comparison of Treatments A vs B and Treatments A vs C, respectively.
A single oral dose of 80 mg of artemether and 480 mg of lumefantrine (4 tablets) was administered to healthy adults as follows: Treatment A, fully dispersed in
water; Treatment B, swallowed with water after crushing to coarse particles; Treatment C, swallowed with water without previous crushing.
Figure 2 Mean plasma concentration-time profiles (linear scale) of artemether, dihydroartemisinin and lumefantrine in healthy
subjects (n = 48). DHA = dihydroartemisinin. A single oral dose of 80 mg of artemether and 480 mg of lumefantrine (4 tablets) was
administered to healthy adults as dispersible tablet (Treatment A, fully dispersed in water), crushed tablet (Treatment B, swallowed with water
after crushing to coarse particles) or intact tablet (Treatment C, swallowed with water without previous crushing). Bars represent one standard
deviation.
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criterion. Mean Cmax of artemether was 17% higher with
the dispersible tablet compared to the tablet adminis-
tered crushed, and the upper boundary of the equiva-
lence range was marginally exceeded (Table 2). For all
analytes, median tmax was virtually identical between the
dispersible tablet and the tablet administered crushed.
No notable difference in t1/2 was observed.
Dispersible tablet versus tablet administered intact
After administration of A-L as dispersible tablet (Treat-
ment A) and intact (uncrushed) tablet (Treatment C),
some differences in artemether and DHA pharmacoki-
netics were observed, while bioequivalence criteria were
met for lumefantrine AUC0-tlast,A U C 0-inf and Cmax
(Table 2). Exposure values (AUC0-tlast and AUC0-inf)f o r
artemether and DHA were 20% and 22-31%, respec-
tively, lower with the dispersible tablet compared to the
intact tablet, with 90% CIs not including unity and
being outside the bioequivalence range (Table 2). Like-
wise, administration of A-L as dispersible tablet resulted
in a 27% (artemether) and 35% (DHA) lower Cmax com-
pared to treatment with intact tablet. For all analytes,
median tmax and mean t1/2 were comparable between
the dispersible tablet and the tablet administered intact
(i.e. uncrushed).
Tablet administered crushed versus tablet administered
intact
The comparison of the tablet administered crushed
(Treatment B) and the intact tablet (Treatment C) was
not prospectively defined in the study protocol, and no
statistical test was performed. Nevertheless, upon
inspection of arithmetic means (Table 1), it is apparent
that there were notable differences in the exposure to
artemether and DHA between the crushed and intact
tablets, with about 20 to 45% lower AUC0-tlast,A U C 0-inf
and Cmax values for the tablet administered crushed.
The pharmacokinetics of lumefantrine was similar for
the two treatments. Overall, the descriptive differences
in artemether and DHA bioavailability parameters
observed between Treatments B and C were comparable
to those seen between Treatments A and C.
Clinical observations
Single doses of A-L given as dispersible tablets and
tablets (crushed or intact) were overall well tolerated.
Thirty-two subjects reported 75 adverse events during
the study without any clinically relevant difference
between treatments. Fewer subjects reported adverse
events in Treatment group C (intact tablets), most likely
due to the absence of a bitter taste caused by dispersed
or crushed A-L tablets. The most commonly reported
adverse event was mild-to-moderate headache for all
three treatments. One subject in Treatment group B
(crushed tablets) reported severe cystitis, which was
considered unrelated to study medication; the event
resolved upon antibiotic treatment. There were no clini-
cally relevant changes in clinical laboratory parameters,
electrocardiograms or vital signs over the study course.
Discussion
During early clinical development of A-L dispersible
tablet, one study investigated the palatability of three fla-
vours of A-L in healthy African schoolchildren using an
oral suspension formulation prepared immediately prior
to tasting from powder-in-bottle suspended with water.
Another study assessed the relative bioavailability of
artemether, DHA and lumefantrine from the novel A-L
dispersible tablet formulation compared with the tablet
(crushed and intact) in healthy European adults. The
principal findings of these two studies can be summar-
ized as follows: (1) All three tested flavours (strawberry,
orange and cherry) appeared appropriate to improve the
t a s t eo fA - Lb u tc h e r r yw a so v e r a l lp r e f e r r e db yc h i l -
dren; (2) exposure to artemether, DHA and lumefan-
trine was comparable for the dispersible and crushed
tablet formulations in healthy adults; and (3) there were
differences of the same magnitude in the exposure to
artemether and DHA between the dispersible tablet and
the intact tablet, and between the crushed and intact
t a b l e t si na d u l th e a l t h ys u b j e c t s ,w h i l ee x p o s u r et o
lumefantrine was similar in these comparisons.
The cherry flavour appeared appropriate to assure a
high acceptability of A-L dispersible tablet in small
infants and children. However, caveats to this conclu-
s i o na r et h es m a l ls a m p l es i z ea n dt h a tt h ec h i l d r e n
investigated were healthy schoolchildren, which may
limit the generalizability of results from this palatability
study to other populations from other areas. Neverthe-
less, the cherry flavour was selected for further clinical
development of the A-L dispersible tablet. Even though
the cherry fruit is not native to Africa, it is often found
in soft drinks and other medications such as antibiotic
syrups [3]. As such, this flavour is familiar to African
children.
Following the palatability study, the pharmacokinetic
performance of the A-L dispersible tablet was investi-
gated in a relative bioavailability study. So far, the
crushed tablet was the usual way to administer A-L to
infants and children, and dosing recommendations for
the paediatric population were originally made accord-
ingly [3]. Therefore, the primary objective of the relative
bioavailability study was the comparison between the
novel A-L dispersible tablet and the crushed tablet in
healthy subjects before embarking on a large efficacy
and safety study in children with malaria. Although it
was not the intention of the study to formally prove
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that the dispersible and crushed tablets delivered bioe-
quivalent artemether, DHA and lumefantrine exposure
(AUC); bioequivalence was also shown for DHA and
lumefantrine Cmax. The slightly increased artemether
Cmax (17%) following administration of A-L dispersible
tablet is judged clinically irrelevant considering the
background variability of this parameter. The usefulness
of the dispersible tablet has been subsequently con-
firmed in a multicenter, investigator-blinded, rando-
mized, non-inferiority study which compared the
efficacy and safety of A-L dispersible tablet and the
tablet administered crushed in 899 African infants and
children with uncomplicated falciparum malaria. The
dispersible formulation was as efficacious as the crushed
tablet, and had a similar safety profile [24]. Within that
study, the similarity of artemether, DHA and lumefan-
trine pharmacokinetics between the dispersible and the
crushed tablet formulations has been confirmed in the
target population [13,24]. Hence, the transition to the
new dispersible tablet of A-L is not thought to present
any significant challenges as the dosing pattern is the
same as for the tablet administered crushed. In fact, the
A-L dispersible tablet has been approved already by
more than 20 countries in Africa, with more countries
to follow in the near future [3].
The statistical compariso no ft h ep l a s m ae x p o s u r e
parameters between the A-L dispersible tablet and the
intact tablet yielded significantly lower AUC and Cmax
values for artemether (by 20% and 27%, respectively)
and DHA (by 22-31% and 35%, respectively) following
intake of the dispersible tablet. Similar descriptive differ-
ences were seen between the crushed and intact tablet.
Exposure to lumefantrine, however, was similar for the
three treatments. Hence, it appears that administering
A-L as an oral suspension (prepared from either the dis-
persible tablet or the crushed tablet) had an impact on
artemether and DHA bioavailability, but not on lume-
fantrine. The pharmacokinetic results obtained for the
intact tablet were in accordance with a previous study
in healthy subjects, which used an identical administra-
tion and blood sampling design [12,25]. In vitro dissolu-
tion profiles of the dispersible tablet and both the
crushed and intact tablets (from the same batches as
used in the present study) were similar for artemether
and lumefantrine (Novartis, data on file). Loss of study
drug during preparation or administration of study med-
ication can be excluded given the highly standardized
procedures applied, and also because no decrease in
lumefantrine exposure was observed. There is no proven
explanation for the observed differences in relative bioa-
vailability of artemether and its metabolite DHA
between the suspension (dispersible or crushed tablet)
and the intact tablet. However, as artemether is known
to be chemically unstable under acidic conditions [26],
it can be hypothesized that the extent of degradation in
the stomach may differ between a solid dosage form and
a suspension. As acid-catalyzed degradation of arte-
mether cannot occur until the drug enters solution and
the dissolution process is expected to take longer for
the intact tablet than for the suspension, a larger frac-
tion of the suspension dose as compared to the intact
tablet dose may be expected to decompose. This may
finally result in a reduced absorption and lower bioavail-
ability of artemether. The observation that Cmax and
AUC of artemether and its metabolite DHA vary in the
same proportions supports this hypothesis. The slightly
lower exposure to artemether and DHA, however, had
no impact on clinical outcomes as demonstrated in a
large clinical trial [24]. The dispersible tablet and the
tablet administered crushed were both highly effective
and appeared well tolerated and safe, consistent with
historical data gathered with the intact tablet [9,27-29].
Conclusions
The data of these two studies suggested that cherry is a
suitable flavour for the development of an A-L dispersi-
ble tablet, and demonstrated that the pharmacokinetic
characteristics of artemether, DHA and lumefantrine are
similar for the dispersible and crushed A-L tablet for-
mulations in adult healthy volunteers. Thus, a cherry-
flavoured A-L dispersible tablet was selected for further
clinical development in patients.
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